In the sixth and final part of the latest CAR-T cell therapy mini-series, we take a look at a really key factor that will need to be addressed if we want to move forward in both hematologic and solid tumours in terms of improved outcomes.
To be clear, this is not about the obvious – tackling immune suppression – but something entirely different!
Now, that might well mean incorporating new regimens in the process or it could lead to version 3.0 in terms of new constructs to be tested in the clinic in due course.
What’s not to like?
Added bonus in this review is that it’s not one voice expressed here, but rather the consolidated perspective of four different experts, so you can quickly see clarity and differences of opinion on several topics…